Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07531043 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults
A Phase 3 study, sponsored by Alcon Research.
- Not yet
- Registry status
- Phase 3
- Development phase
- 230
- Enrollment target
NCT07531043: Clinical Trial Phase 3 study, sponsored by Alcon Research.
NCT07531043 is a Phase 3 study that has not yet begun recruiting, run by Alcon Research. The registered enrollment target is 230 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07531043, a Phase 3 study, has not yet begun recruiting, sponsored by Alcon Research.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 230 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.
Primary Outcome
Ocular redness will be assessed by the investigator and recorded per the Ora Calibra® Ocular Hyperemia Scale, which ranges from 0 to 4 in half-point increments (0.0 = none; 1.0 = mild redness; 2.0 = moderate redness; 3.0 = severe redness; and 4.0 = extremely severe redness). Change from baseline, calculated as post-instillation minus baseline score, can range between -4 and +2.5. Positive values indicate increased ocular redness (worsening), zero indicates no change, and negative values indicate
Interventions
- DRUG Vehicle
- DRUG Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 230 participants |
| Start Date | 2026-10 |
| Est. Completion | 2027-02 |
| Phase | Phase 3 |
What is known before NCT07531043 opens enrollment
NCT07531043 is an interventional study that assigns participants to a tested intervention. The registered 230 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (70% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT07531043 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07531043 about?
NCT07531043 is a clinical study titled "Efficacy and Safety of FID 123472 Ophthalmic Solution for Ocular Redness in Adults". The purpose of this study is to evaluate the efficacy and safety of an investigational ophthalmic solution in adults with ocular redness due to minor eye irritations.
What is the current status of trial NCT07531043?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 230 participants. The study started on 2026-10. Estimated completion is 2027-02.
What interventions are being tested in trial NCT07531043?
The interventions under investigation include: Vehicle (DRUG), Apraclonidine Ophthalmic Solution, 0.125% Unit Dose Preservative Free (DRUG).
Who is sponsoring clinical trial NCT07531043?
This trial is sponsored by Alcon Research, which has 275 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07531043's enrollment target sits among peer trials
230 1304th of 2000 higher than 692 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02710253 · 230 participants · Phase 2
Salvage Radiation Therapy in Treating Patients With Metastatic Cancer That Has Progressed After Systemic Immunotherapy
- NCT02777879 · 230 participants
Lung Microbiome and Inflammation in Early COPD
- NCT03824483 · 230 participants · Phase 2
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
- NCT03833622 · 230 participants · NA
Shared Decision Making to Improve Goals of Care in the ED
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia